JDRF’s Mission to Prevent Type 1 Diabetes in High-Risk Populations

Type 1 diabetes (T1D) is an autoimmune disease that strikes when the body’s immune system mistakenly destroys the insulin-producing beta cells in the pancreas. Unlike type 2 diabetes, which is often linked to lifestyle factors, T1D typically emerges early in life and requires lifelong insulin therapy. For those with a family history or genetic predisposition, the risk is elevated—sometimes dramatically. The Juvenile Diabetes Research Foundation (JDRF) has dedicated significant resources to understanding why this autoimmune attack begins and, more importantly, how to stop it before clinical symptoms appear. Their work focuses on high-risk populations—people with first-degree relatives already living with T1D, individuals carrying specific HLA haplotypes, and those who show early signs of autoantibodies. By narrowing the scope to these groups, JDRF aims to make prevention a reality within a generation.

Understanding the High-Risk Profile

Not everyone with a genetic marker develops T1D. The disease requires a trigger—often a viral infection or environmental factor—that sets off the immune cascade. JDRF-funded studies have identified several key indicators that place someone in a high-risk category:

  • Familial history: Having a sibling, parent, or child with T1D increases the lifetime risk from about 0.4% in the general population to 6–8% in first-degree relatives.
  • Genetic markers: Certain HLA-DR and HLA-DQ alleles are strongly associated with T1D, especially in people of European descent.
  • Islet autoantibodies: The presence of two or more autoantibodies (against insulin, GAD, IA-2, or ZnT8) nearly guarantees progression to clinical diabetes within 10–15 years.
  • Age at seroconversion: Children who develop autoantibodies before age 5 are at the highest risk of rapid progression.

JDRF’s prevention research leverages these biomarkers to enroll participants in studies designed to intercept the disease process. This targeted approach maximizes statistical power and ethical efficiency, as resources are directed toward those most likely to benefit.

Immunotherapy: Calming the Autoimmune Storm

The most promising avenue for T1D prevention is immunotherapy—treatments that retrain the immune system to tolerate beta cells rather than attack them. JDRF has been a leading funder of clinical trials exploring several classes of immunomodulators.

Anti-CD3 Monoclonal Antibodies (Teplizumab)

Teplizumab, a humanized anti-CD3 antibody, made headlines when a JDRF-supported trial demonstrated that a single 14-day course could delay the onset of clinical T1D by a median of more than two years in high-risk relatives. The drug works by dampening the activity of autoreactive T cells while preserving regulatory T cell function. JDRF’s investment in early-phase studies and later pivotal trials was instrumental in gaining FDA approval in 2022 for delaying T1D in stage 2 patients. Ongoing research is testing whether repeated courses or combination therapies can extend this delay even further—potentially indefinitely.

Antigen-Specific Immunotherapy

Another approach is to expose the immune system to small doses of beta-cell antigens in a way that induces tolerance rather than attack. JDRF funds trials using oral insulin, intranasal insulin, and peptide fragments of GAD and proinsulin. Early results from the Primary Oral Insulin Trial and the Pre-POINT study suggest that early exposure (especially in infants) may reduce the development of multiple autoantibodies. The challenge is identifying the right dose, timing, and route—JDRF’s network of clinical centers continues to refine these parameters.

Regulatory T Cell Therapy

JDRF has also backed pioneering work in cellular therapy, specifically the expansion and reinfusion of a patient’s own regulatory T cells (Tregs). Early safety trials show that Treg infusions can preserve C-peptide levels (a marker of endogenous insulin production) in newly diagnosed patients. The next step is to test whether this intervention, given before onset, can prevent the initial wave of beta-cell destruction. JDRF established the Treg Consortium to accelerate this research across academic and industry partners.

Vaccine-Based Prevention Strategies

While vaccines are typically associated with infectious diseases, JDRF is investigating whether they can protect pancreatic beta cells from autoimmune attack or prevent the environmental triggers that initiate it.

Enterovirus Vaccines

Epidemiological evidence links enterovirus infections—particularly Coxsackie B viruses—with the appearance of islet autoantibodies in genetically susceptible children. JDRF funds the development of an enterovirus vaccine aimed at high-risk infants. The hypothesis is straightforward: if you can prevent the viral trigger, you may prevent the autoimmune cascade. Preclinical models are promising, and phase 1 safety trials in adults are underway. A successful vaccine could be given alongside routine childhood immunizations.

Tolerogenic Vaccines

Rather than targeting a pathogen, tolerogenic vaccines aim to teach the immune system to recognize beta-cell proteins as “self.” JDRF supports research using virus-like particles or nanoparticles coated with insulin or GAD peptides. These “vaccines” induce regulatory responses that suppress autoimmunity without broadly suppressing the immune system. Early results in animal models show durable protection from diabetes, and a phase 1 trial in humans is in planning.

Genetic Screening and Biomarker Development

Prevention cannot happen without early identification. JDRF has invested heavily in large-scale genetic screening programs that identify high-risk individuals before symptoms arise.

The Environmental Determinants of Diabetes in the Young (TEDDY) Study

JDRF is a major funder of TEDDY, an international consortium that has followed genetically at-risk children from birth for over 15 years. The study has identified dozens of environmental triggers—dietary factors, infections, gut microbiome composition—that associate with seroconversion. Data from TEDDY directly informs the design of prevention trials, helping researchers decide when and whom to treat. For example, TEDDY found that early introduction of gluten or cow’s milk does not significantly increase risk, but enterovirus infections in the first year do. These insights shape vaccine and dietary intervention trials.

Autoantibody Screening Programs

JDRF supports widespread autoantibody screening, such as the Autoimmunity Screening for Kids (ASK) initiative. By testing children for islet autoantibodies as part of routine pediatric care, ASK can identify stage 1 T1D (presymptomatic, multiple autoantibodies) years before glucose levels rise. JDRF funds the infrastructure to ensure families receive counseling and are connected to prevention trials. The goal is to make screening as routine as newborn hearing tests.

Gene Editing and Cellular Reprogramming

Looking further ahead, JDRF is funding exploratory research into gene-editing technologies that could eliminate the genetic susceptibility to T1D altogether.

CRISPR-Based Strategies

Scientists are using CRISPR-Cas9 to edit immune cells from high-risk individuals, removing the autoreactive T cell receptors that drive beta-cell destruction. JDRF supports proof-of-concept studies in humanized mouse models. If safe in humans, a one-time infusion of edited T cells could provide lifelong protection. Separately, researchers are investigating whether correcting HLA risk alleles in stem cells could produce beta cells that are invisible to the immune system. While these approaches are years from the clinic, JDRF’s early investment ensures the foundational science is robust.

Stem Cell-Derived Beta Cell Replacement

For those who already have T1D, JDRF funds efforts to create immune-evasive stem cell-derived beta cells. But for prevention, the idea is to implant these cells into high-risk individuals before their own beta cells are fully destroyed. The cells would serve as a “buffer,” maintaining normal glucose control even if the autoimmune attack continues. JDRF is working with companies like Vertex and ViaCyte to trial these implantable devices. Early data show that encapsulated cells can survive without immunosuppression, paving the way for preemptive therapy.

Collaboration and Community Engagement

JDRF’s prevention research is not conducted in a vacuum. The foundation fosters partnerships with academic institutions, pharmaceutical companies, regulatory agencies, and, crucially, the high-risk community itself.

The Network of Clinical Centers

Through the JDRF-funded Clinical Trial Network and the International Diabetes Immunotherapy Consortium, centers across North America, Europe, and Australia collaborate to recruit participants and share data. This infrastructure reduces duplication of effort and accelerates the testing of new therapies. For example, a single participant may contribute data to both an immunotherapy trial and a natural history study like TrialNet.

Patient and Family Advisory Boards

JDRF includes high-risk families in trial design through regular advisory boards. These voices ensure that the burdens of participation—frequent blood draws, travel, time away from work—are minimized. They also help researchers communicate the uncertain benefits of prevention trials, respecting the hopes and anxieties of families living at risk. JDRF’s approach is transparent: no stage 1 or stage 2 trial guarantees prevention, but every trial brings researchers closer.

How Teachers and Students Can Get Involved

JDRF’s prevention mission extends beyond the lab. Education and awareness in schools can identify undiagnosed children and support those living with T1D. Here are concrete steps that educators and students can take:

  1. Host a JDRF One Walk event at your school to raise funds for prevention research. School teams can form months ahead and turn the walk into a health science lesson.
  2. Integrate T1D genetics into biology curricula. Use JDRF’s freely available modules on autoantibody testing and clinical trial design to teach real-world immunology.
  3. Start a student club focused on diabetes awareness. Students can organize educational assemblies, sell bracelets to fund JDRF grants, or write to state legislators about supporting autoantibody screening in schools.
  4. Promote the ASK screening program at parent-teacher conferences. Many families are unaware that a simple blood test can reveal T1D risk years before symptoms. JDRF offers brochures and videos that can be displayed in school health offices.
  5. Encourage participation in clinical trials. High school students with a first-degree relative with T1D may be eligible for prevention studies. JDRF’s website lists active trials and provides guidance on how to enroll.

Looking Forward: The Path to Prevention

Preventing T1D is no longer a dream—it is a tangible goal supported by an expanding body of science. JDRF’s strategic research portfolio, built over decades, now includes multiple interventions that have delayed or blocked the disease in high-risk populations. The median delay from teplizumab is already the basis for a new standard of care, and next-generation immunotherapies aim for permanent tolerance.

Yet challenges remain. Not all high-risk individuals are eligible for existing therapies, and the cost of screening and treatment must be addressed to ensure equity. JDRF advocates for insurance coverage of autoantibody testing and for Medicare/Medicaid inclusion of teplizumab. The foundation also funds health services research to identify barriers to uptake and to ensure that prevention reaches communities of color, which are historically underrepresented in T1D studies.

The ultimate goal is a world where no child develops T1D. JDRF is financing the road to that destination with relentless investment in basic science, translational research, and community engagement. With continued public support, prevention is not just possible—it is inevitable.

External Resources and Further Reading

For more detailed information on JDRF’s prevention portfolio, visit the official JDRF prevention research page. To learn about enrolling in clinical trials, check ClinicalTrials.gov for current studies. The TEDDY study publishes regular updates at TEDDY. For school resources and curriculum integration, the JDRF Teacher’s Toolkit provides downloadable lesson plans. Finally, the NIDDK autoantibody testing overview explains the science behind current screening technologies.